Enhancing CHK1 inhibitor lethality in glioblastoma

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

(2011) X.-Y. Pei et al.   BLOOD

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death

(2011) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Glioblastoma multiforme with an unusual location and clinical course

(2011) É. Gömöri et al.   CLINICAL NEUROPATHOLOGY

CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle

(2011) P. Dent et al.   MOLECULAR INTERVENTIONS

Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo

(2010) Y. Dai et al.   BLOOD

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

(2010) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways

(2010) F. Yang et al.   MOLECULAR CANCER RESEARCH

Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells

(2010) C. Mitchell et al.   MOLECULAR PHARMACOLOGY

Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma

(2010) Hossein A Hamed et al.   MOLECULAR THERAPY

Predicting the efficacy of radiotherapy in individual glioblastoma patientsin vivo:a mathematical modeling approach

(2010) R Rockne et al.   PHYSICS IN MEDICINE AND BIOLOGY

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

Glioblastoma multiforme: a review of where we have been and where we are going

(2009) Cory Adamson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Glioblastoma multiforme: a review of therapeutic targets

(2009) Okezie O Kanu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing

(2009) A. P. Martin et al.   MOLECULAR PHARMACOLOGY

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

(2008) S. Ashwell et al.   CLINICAL CANCER RESEARCH

Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells

(2008) A. Yacoub et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling

(2008) A. Yacoub et al.   MOLECULAR CANCER THERAPEUTICS

Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo

(2008) H. Hamed et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

(2008) F. Yang et al.   MOLECULAR CANCER THERAPEUTICS